1	[	[	O	(	O	21	DEP	-1
2	Prognostic	Prognostic	B-NP	JJ	O	3	NMOD	-1
3	significance	significance	I-NP	NN	O	21	DEP	-1
4	of	of	B-PP	IN	O	3	NMOD	-1
5	cellular	cellular	B-NP	JJ	B-protein	9	NMOD	-1
6	vascular	vascular	I-NP	JJ	I-protein	9	NMOD	-1
7	endothelial	endothelial	I-NP	JJ	I-protein	9	NMOD	-1
8	growth	growth	I-NP	NN	I-protein	9	NMOD	0
9	factor	factor	I-NP	NN	I-protein	13	NMOD	-1
10	(	(	O	(	O	12	DEP	-1
11	VEGF	VEGF	B-NP	NN	B-protein	12	DEP	-1
12	)	)	O	)	O	9	NMOD	-1
13	expression	expression	B-NP	NN	O	4	PMOD	9	expression
14	in	in	B-PP	IN	O	13	NMOD	-1
15	the	the	B-NP	DT	O	16	NMOD	-1
16	course	course	I-NP	NN	O	14	PMOD	-1
17	of	of	B-PP	IN	O	16	NMOD	-1
18	chronic	chronic	B-NP	JJ	O	20	NMOD	-1
19	myeloid	myeloid	I-NP	JJ	O	20	NMOD	-1
20	leukaemia	leukaemia	I-NP	NN	O	17	PMOD	-1
21	]	]	O	)	O	0	ROOT	-1

1	INTRODUCTION	INTRODUCTION	B-NP	NN	O	4	NMOD	0
2	:	:	O	:	O	1	P	-1
3	Increased	Increase	B-NP	VBN	O	4	NMOD	17	Increased
4	angiogenesis	angiogenesis	I-NP	NN	O	8	SUB	3	angiogenesis
5	in	in	B-PP	IN	O	4	NMOD	-1
6	bone	bone	B-NP	NN	O	7	NMOD	-1
7	marrow	marrow	I-NP	NN	O	5	PMOD	-1
8	is	be	B-VP	VBZ	O	0	ROOT	-1
9	one	one	B-NP	CD	O	8	PRD	-1
10	of	of	B-PP	IN	O	9	NMOD	-1
11	the	the	B-NP	DT	O	12	NMOD	-1
12	characteristics	characteristic	I-NP	NNS	O	10	PMOD	-1
13	of	of	B-PP	IN	O	12	NMOD	-1
14	chronic	chronic	B-NP	JJ	O	16	NMOD	-1
15	myeloid	myeloid	I-NP	JJ	O	16	NMOD	-1
16	leukaemia	leukaemia	I-NP	NN	O	24	NMOD	-1
17	(	(	O	(	O	19	DEP	-1
18	CML	CML	B-NP	NN	O	19	DEP	-1
19	)	)	O	)	O	16	NMOD	-1
20	,	,	O	,	O	24	P	-1
21	a	a	B-NP	DT	O	24	NMOD	-1
22	clonal	clonal	I-NP	JJ	O	24	NMOD	-1
23	myeloproliferative	myeloproliferative	I-NP	JJ	O	24	NMOD	-1
24	disorder	disorder	I-NP	NN	O	13	PMOD	-1
25	that	that	B-NP	WDT	O	24	NMOD	-1
26	expresses	express	B-VP	VBZ	O	25	SBAR	-1
27	a	a	B-NP	DT	O	30	NMOD	-1
28	chimeric	chimeric	I-NP	JJ	B-protein	30	NMOD	-1
29	bcr/abl	bcr/abl	I-NP	NN	I-protein	30	NMOD	-1
30	protein	protein	I-NP	NN	I-protein	26	OBJ	-1
31	.	.	O	.	O	8	P	-1

1	Vascular	Vascular	B-NP	JJ	B-protein	4	NMOD	-1
2	endothelial	endothelial	I-NP	JJ	I-protein	4	NMOD	-1
3	growth	growth	I-NP	NN	I-protein	4	NMOD	0
4	factor	factor	I-NP	NN	I-protein	8	SUB	-1
5	(	(	O	(	O	7	DEP	-1
6	VEGF	VEGF	B-NP	NN	B-protein	7	DEP	-1
7	)	)	O	)	O	4	NMOD	-1
8	is	be	B-VP	VBZ	O	0	ROOT	-1
9	one	one	B-NP	CD	O	8	PRD	-1
10	of	of	B-PP	IN	O	9	NMOD	-1
11	the	the	B-NP	DT	O	13	NMOD	-1
12	most	most	I-NP	RBS	O	13	AMOD	-1
13	potent	potent	I-NP	JJ	O	17	NMOD	-1
14	and	and	O	CC	O	17	NMOD	-1
15	a	a	B-NP	DT	O	17	NMOD	-1
16	specific	specific	I-NP	JJ	O	17	NMOD	-1
17	regulator	regulator	I-NP	NN	O	10	PMOD	16	regulator
18	of	of	B-PP	IN	O	17	NMOD	-1
19	angiogenesis	angiogenesis	B-NP	NN	O	18	PMOD	3	angiogenesis
20	which	which	B-NP	WDT	O	17	NMOD	-1
21	principally	principally	B-ADVP	RB	O	22	VMOD	-1
22	targets	target	B-VP	VBZ	O	20	SBAR	0
23	endothelial	endothelial	B-NP	JJ	B-cell_type	24	NMOD	-1
24	cells	cell	I-NP	NNS	I-cell_type	22	OBJ	-1
25	and	and	O	CC	O	22	VMOD	-1
26	regulates	regulate	B-VP	VBZ	O	22	VMOD	16	regulates
27	several	several	B-NP	JJ	O	26	OBJ	-1
28	of	of	B-PP	IN	O	27	NMOD	-1
29	their	their	B-NP	PRP$	O	30	NMOD	-1
30	functions	function	I-NP	NNS	O	28	PMOD	0
31	,	,	O	,	O	27	P	-1
32	including	include	B-PP	VBG	O	27	NMOD	-1
33	mitogenesis	mitogenesis	B-NP	NN	O	37	NMOD	-1
34	,	,	I-NP	,	O	37	P	-1
35	permeability	permeability	I-NP	NN	O	37	NMOD	-1
36	and	and	I-NP	CC	O	37	NMOD	-1
37	migration	migration	I-NP	NN	O	32	PMOD	0
38	.	.	O	.	O	8	P	-1

1	The	The	B-NP	DT	O	2	NMOD	-1
2	impact	impact	I-NP	NN	O	14	SUB	0
3	of	of	B-PP	IN	O	2	NMOD	-1
4	elevated	elevated	B-NP	JJ	O	6	NMOD	17	elevated
5	VEGF	VEGF	I-NP	NN	B-protein	6	NMOD	-1
6	expression	expression	I-NP	NN	O	3	PMOD	9	expression
7	on	on	B-PP	IN	O	2	NMOD	-1
8	the	the	B-NP	DT	O	9	NMOD	-1
9	course	course	I-NP	NN	O	7	PMOD	-1
10	of	of	B-PP	IN	O	9	NMOD	-1
11	chronic	chronic	B-NP	JJ	O	13	NMOD	-1
12	myeloid	myeloid	I-NP	JJ	O	13	NMOD	-1
13	leukaemia	leukaemia	I-NP	NN	O	10	PMOD	-1
14	is	be	B-VP	VBZ	O	0	ROOT	-1
15	unknown	unknown	B-ADJP	JJ	O	14	PRD	-1
16	.	.	O	.	O	14	P	-1

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT	-1
2	:	:	O	:	O	1	P	-1
3	The	The	B-NP	DT	O	4	NMOD	-1
4	aim	aim	I-NP	NN	O	8	SUB	-1
5	of	of	B-PP	IN	O	4	NMOD	-1
6	this	this	B-NP	DT	O	7	NMOD	-1
7	study	study	I-NP	NN	O	5	PMOD	-1
8	was	be	B-VP	VBD	O	1	NMOD	-1
9	the	the	B-NP	DT	O	10	NMOD	-1
10	follow-up	follow-up	I-NP	NN	O	8	PRD	-1
11	of	of	B-PP	IN	O	10	NMOD	-1
12	VEGF	VEGF	B-NP	NN	B-protein	13	NMOD	-1
13	expression	expression	I-NP	NN	O	11	PMOD	9	expression
14	during	during	B-PP	IN	O	8	VMOD	-1
15	the	the	B-NP	DT	O	16	NMOD	-1
16	course	course	I-NP	NN	O	14	PMOD	-1
17	of	of	B-PP	IN	O	16	NMOD	-1
18	CML	CML	B-NP	NN	O	17	PMOD	-1
19	.	.	O	.	O	8	P	-1

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT	-1
2	:	:	O	:	O	1	P	-1
3	We	We	B-NP	PRP	O	4	SUB	-1
4	studied	study	B-VP	VBD	O	1	NMOD	-1
5	VEGF	VEGF	B-NP	NN	B-protein	6	NMOD	-1
6	expression	expression	I-NP	NN	O	4	OBJ	9	expression
7	of	of	B-PP	IN	O	6	NMOD	-1
8	85	85	B-NP	CD	O	10	NMOD	-1
9	CML	CML	I-NP	NN	O	10	NMOD	-1
10	patients	patient	I-NP	NNS	O	7	PMOD	-1
11	(	(	O	(	O	20	DEP	-1
12	median	median	B-NP	JJ	O	15	NMOD	-1
13	age	age	I-NP	NN	O	15	NMOD	-1
14	50	50	B-NP	CD	O	15	NMOD	-1
15	years	year	I-NP	NNS	O	19	NMOD	-1
16	,	,	O	,	O	19	P	-1
17	range	range	B-NP	NN	O	19	NMOD	-1
18	16-75	16-75	B-NP	CD	O	19	NMOD	-1
19	years	year	I-NP	NNS	O	20	DEP	-1
20	)	)	O	)	O	10	NMOD	-1
21	.	.	O	.	O	1	P	-1

1	At	At	B-PP	IN	O	10	VMOD	-1
2	the	the	B-NP	DT	O	3	NMOD	-1
3	commencement	commencement	I-NP	NN	O	1	PMOD	-1
4	of	of	B-PP	IN	O	3	NMOD	-1
5	the	the	B-NP	DT	O	6	NMOD	-1
6	study	study	I-NP	NN	O	4	PMOD	-1
7	,	,	O	,	O	10	P	-1
8	29	29	B-NP	CD	O	9	NMOD	-1
9	patients	patient	I-NP	NNS	O	10	SUB	-1
10	were	be	B-VP	VBD	O	0	ROOT	-1
11	in	in	B-PP	IN	O	10	VMOD	-1
12	chronic	chronic	B-NP	JJ	O	13	NMOD	-1
13	phase	phase	I-NP	NN	O	11	PMOD	-1
14	(	(	O	(	O	16	DEP	-1
15	CP	CP	B-NP	NN	B-DNA	16	DEP	-1
16	)	)	O	)	O	13	NMOD	-1
17	,	,	O	,	O	10	P	-1
18	25	25	B-NP	CD	O	28	NMOD	-1
19	in	in	B-PP	IN	O	18	NMOD	-1
20	an	an	B-NP	DT	O	22	NMOD	-1
21	accelerated	accelerate	I-NP	VBN	O	22	NMOD	0
22	phase	phase	I-NP	NN	O	19	PMOD	-1
23	(	(	O	(	O	25	DEP	-1
24	AP	AP	B-NP	NN	B-protein	25	DEP	-1
25	)	)	O	)	O	22	NMOD	-1
26	,	,	O	,	O	18	P	-1
27	and	and	O	CC	O	28	NMOD	-1
28	31	31	B-NP	CD	O	10	VMOD	-1
29	in	in	B-PP	IN	O	28	NMOD	-1
30	the	the	B-NP	DT	O	32	NMOD	-1
31	blast	blast	I-NP	NN	O	32	NMOD	-1
32	crisis	crisis	I-NP	NN	O	29	PMOD	-1
33	(	(	O	(	O	35	DEP	-1
34	BC	BC	B-NP	NN	B-cell_type	35	DEP	-1
35	)	)	O	)	O	32	NMOD	-1
36	.	.	O	.	O	10	P	-1

1	The	The	B-NP	DT	O	3	NMOD	-1
2	temporal	temporal	I-NP	JJ	O	3	NMOD	-1
3	expression	expression	I-NP	NN	O	13	NMOD	9	expression
4	(	(	O	(	O	11	DEP	-1
5	percentage	percentage	B-NP	NN	O	6	NMOD	-1
6	positivity	positivity	I-NP	NN	O	11	DEP	-1
7	per	per	B-PP	IN	O	6	NMOD	-1
8	1000	1000	B-NP	CD	O	10	NMOD	-1
9	analysed	analyse	I-NP	VBN	O	10	NMOD	-1
10	cells	cell	I-NP	NNS	O	7	PMOD	-1
11	)	)	O	)	O	3	NMOD	-1
12	VEGF	VEGF	B-NP	NN	B-protein	13	NMOD	-1
13	proteins	protein	I-NP	NNS	I-protein	19	SUB	-1
14	over	over	B-PP	IN	O	13	NMOD	-1
15	the	the	B-NP	DT	O	16	NMOD	-1
16	course	course	I-NP	NN	O	14	PMOD	-1
17	of	of	B-PP	IN	O	16	NMOD	-1
18	CML	CML	B-NP	NN	O	17	PMOD	-1
19	were	be	B-VP	VBD	O	0	ROOT	-1
20	studied	study	I-VP	VBN	O	19	VC	-1
21	using	use	B-VP	VBG	O	19	VMOD	-1
22	the	the	B-NP	DT	O	28	NMOD	-1
23	immunohistochemical	immunohistochemical	I-NP	JJ	B-protein	28	NMOD	-1
24	technique	technique	I-NP	NN	I-protein	28	NMOD	-1
25	utilizing	utilize	B-VP	VBG	I-protein	28	NMOD	-1
26	relevant	relevant	B-NP	JJ	I-protein	28	NMOD	-1
27	monoclonal	monoclonal	I-NP	JJ	I-protein	28	NMOD	-1
28	antibodies	antibody	I-NP	NNS	I-protein	21	OBJ	-1
29	.	.	O	.	O	19	P	-1

1	It	It	B-NP	PRP	O	2	SUB	-1
2	was	be	B-VP	VBD	O	0	ROOT	-1
3	correlated	correlate	I-VP	VBN	O	2	VC	-1
4	with	with	B-PP	IN	O	3	VMOD	-1
5	the	the	B-NP	DT	O	6	NMOD	-1
6	laboratory	laboratory	I-NP	NN	O	23	NMOD	-1
7	(	(	O	(	O	23	NMOD	-1
8	Hb	Hb	B-NP	NN	B-protein	13	NMOD	-1
9	,	,	O	,	O	13	P	-1
10	WBC	WBC	B-NP	NN	B-protein	13	NMOD	-1
11	and	and	I-NP	CC	O	13	NMOD	-1
12	platelet	platelet	I-NP	NN	O	13	NMOD	-1
13	counts	count	I-NP	NNS	O	23	NMOD	-1
14	,	,	O	,	O	23	P	-1
15	and	and	O	CC	O	23	NMOD	-1
16	the	the	B-NP	DT	O	17	NMOD	-1
17	percentage	percentage	I-NP	NN	O	23	NMOD	-1
18	of	of	B-PP	IN	O	17	NMOD	-1
19	blasts	blast	B-NP	NNS	B-cell_type	18	PMOD	-1
20	)	)	O	)	O	17	NMOD	-1
21	and	and	O	CC	O	23	NMOD	-1
22	clinical	clinical	B-NP	JJ	O	23	NMOD	-1
23	parameters	parameter	I-NP	NNS	O	4	PMOD	-1
24	(	(	O	(	O	23	NMOD	-1
25	organomegaly	organomegaly	B-NP	NN	O	27	NMOD	-1
26	,	,	O	,	O	27	P	-1
27	duration	duration	B-NP	NN	O	24	PMOD	-1
28	of	of	B-PP	IN	O	27	NMOD	-1
29	CP	CP	B-NP	NN	B-DNA	34	NMOD	-1
30	,	,	O	,	O	34	P	-1
31	AP	AP	B-NP	NN	O	34	NMOD	-1
32	,	,	O	,	O	34	P	-1
33	and	and	O	CC	O	34	NMOD	-1
34	BC	BC	B-NP	NN	B-cell_type	28	PMOD	-1
35	)	)	O	)	O	34	NMOD	-1
36	of	of	B-PP	IN	O	34	NMOD	-1
37	disease	disease	B-NP	NN	O	38	NMOD	-1
38	progression	progression	I-NP	NN	O	36	PMOD	0
39	.	.	O	.	O	2	P	-1

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT	0
2	:	:	O	:	O	1	P	-1
3	The	The	B-NP	DT	O	6	NMOD	-1
4	expression	expression	I-NP	NN	O	6	NMOD	9	expression
5	ofVEGF	ofVEGF	I-NP	NN	O	6	NMOD	-1
6	protein	protein	I-NP	NN	O	7	SUB	-1
7	was	be	B-VP	VBD	O	1	NMOD	-1
8	most	most	B-ADJP	RBS	O	9	AMOD	-1
9	pronounced	pronounced	I-ADJP	JJ	O	7	PRD	-1
10	in	in	B-PP	IN	O	7	VMOD	-1
11	AP	AP	B-NP	NN	O	10	PMOD	-1
12	(	(	O	(	O	16	DEP	-1
13	ANOVA	ANOVA	B-NP	NN	O	15	NMOD	-1
14	,	,	O	,	O	15	P	-1
15	p=0.033	p=0.033	B-NP	NN	O	16	DEP	-1
16	)	)	O	)	O	11	NMOD	-1
17	.	.	O	.	O	1	P	-1

1	The	The	B-NP	DT	O	2	NMOD	-1
2	level	level	I-NP	NN	O	6	SUB	-1
3	of	of	B-PP	IN	O	2	NMOD	-1
4	VEGF	VEGF	B-NP	NN	B-protein	5	NMOD	-1
5	expression	expression	I-NP	NN	O	3	PMOD	9	expression
6	correlated	correlate	B-VP	VBD	O	0	ROOT	-1
7	inversely	inversely	B-ADVP	RB	O	6	VMOD	-1
8	with	with	B-PP	IN	O	6	VMOD	-1
9	the	the	B-NP	DT	O	10	NMOD	-1
10	degree	degree	I-NP	NN	O	8	PMOD	-1
11	of	of	B-PP	IN	O	10	NMOD	-1
12	splenomegaly	splenomegaly	B-NP	NN	O	11	PMOD	-1
13	(	(	O	(	O	19	DEP	-1
14	Pearson	Pearson	B-NP	NNP	O	18	NMOD	-1
15	,	,	O	,	O	18	P	-1
16	r=-0.400	r=-0.400	B-NP	NN	O	18	NMOD	-1
17	,	,	O	,	O	18	P	-1
18	p=0.011	p=0.011	B-NP	NN	O	19	DEP	-1
19	)	)	O	)	O	6	VMOD	-1
20	.	.	O	.	O	6	P	-1

1	High	High	B-NP	JJ	O	2	NMOD	-1
2	expression	expression	I-NP	NN	O	5	SUB	9	expression
3	of	of	B-PP	IN	O	2	NMOD	-1
4	VEGF	VEGF	B-NP	NN	B-protein	3	PMOD	-1
5	correlated	correlate	B-VP	VBD	O	0	ROOT	-1
6	with	with	B-PP	IN	O	5	VMOD	-1
7	a	a	B-NP	DT	O	10	NMOD	-1
8	shorter	short	I-NP	JJR	O	10	NMOD	-1
9	overall	overall	I-NP	JJ	O	10	NMOD	-1
10	survival	survival	I-NP	NN	O	6	PMOD	0
11	(	(	O	(	O	16	DEP	-1
12	log	log	B-NP	NN	O	13	NMOD	-1
13	rank	rank	I-NP	NN	O	15	NMOD	-1
14	,	,	O	,	O	15	P	-1
15	p=0.042	p=0.042	B-NP	NN	O	16	DEP	-1
16	)	)	O	)	O	10	NMOD	-1
17	.	.	O	.	O	5	P	-1

1	CONCLUSION	CONCLUSION	B-NP	NN	O	0	ROOT	-1
2	:	:	O	:	O	1	P	-1
3	Immunohistochemically	Immunohistochemically	B-NP	RB	O	4	AMOD	-1
4	confirmed	confirm	I-NP	VBN	O	5	NMOD	-1
5	significance	significance	I-NP	NN	O	17	SUB	-1
6	of	of	B-PP	IN	O	5	NMOD	-1
7	the	the	B-NP	DT	O	8	NMOD	-1
8	expression	expression	I-NP	NN	O	6	PMOD	9	expression
9	of	of	B-PP	IN	O	8	NMOD	-1
10	VEGF	VEGF	B-NP	NN	B-protein	9	PMOD	-1
11	in	in	B-PP	IN	O	5	NMOD	-1
12	dependence	dependence	B-NP	NN	O	11	PMOD	-1
13	of	of	B-PP	IN	O	12	NMOD	-1
14	the	the	B-NP	DT	O	16	NMOD	-1
15	CML	CML	I-NP	NN	O	16	NMOD	-1
16	stage	stage	I-NP	NN	O	13	PMOD	-1
17	could	could	B-VP	MD	O	1	NMOD	-1
18	be	be	I-VP	VB	O	17	VC	-1
19	of	of	B-PP	IN	O	18	PRD	-1
20	clinical	clinical	B-NP	JJ	O	21	NMOD	-1
21	importance	importance	I-NP	NN	O	19	PMOD	-1
22	in	in	B-PP	IN	O	18	VMOD	-1
23	deciding	decide	B-VP	VBG	O	22	PMOD	-1
24	on	on	B-PP	IN	O	23	VMOD	-1
25	the	the	B-NP	DT	O	27	NMOD	-1
26	timing	timing	I-NP	NN	O	27	NMOD	-1
27	therapy	therapy	I-NP	NN	O	24	PMOD	0
28	.	.	O	.	O	1	P	-1

1	These	These	B-NP	DT	O	2	NMOD	-1
2	data	datum	I-NP	NNS	O	3	SUB	-1
3	suggest	suggest	B-VP	VBP	O	0	ROOT	-1
4	that	that	B-SBAR	IN	O	15	DEP	-1
5	VEGF	VEGF	B-NP	NN	B-protein	6	SUB	-1
6	plays	play	B-VP	VBZ	O	4	SBAR	-1
7	a	a	B-NP	DT	O	8	NMOD	-1
8	role	role	I-NP	NN	O	6	OBJ	0
9	in	in	B-PP	IN	O	6	VMOD	-1
10	the	the	B-NP	DT	O	11	NMOD	-1
11	biology	biology	I-NP	NN	O	9	PMOD	-1
12	of	of	B-PP	IN	O	11	NMOD	-1
13	CML	CML	B-NP	NN	O	12	PMOD	-1
14	and	and	O	CC	O	15	DEP	-1
15	that	that	B-SBAR	IN	O	3	VMOD	-1
16	VEGF	VEGF	B-NP	NN	B-protein	17	NMOD	-1
17	inhibitors	inhibitor	I-NP	NNS	O	18	SUB	-1
18	should	should	B-VP	MD	O	15	SBAR	-1
19	be	be	I-VP	VB	O	18	VC	-1
20	investigated	investigate	I-VP	VBN	O	19	VC	-1
21	in	in	B-PP	IN	O	20	VMOD	-1
22	CML	CML	B-NP	NN	O	21	PMOD	-1
23	.	.	O	.	O	3	P	-1

